Survival outcomes in patients (pts) with KRAS/NRAS (RAS) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study.
Jean-Yves Douillard
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Merck Serono; Roche
Research Funding - Merck Serono
Josep Tabernero
Consultant or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche; Sanofi ; Taiho Pharmaceutical
Salvatore Siena
Consultant or Advisory Role - Amgen; AstraZeneca; Bayer; Celgene; Health Genomics; Roche; Sanofi
Marc Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Reija Koukakis
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jan-Henrik Terwey
Employment or Leadership Position - Amgen Europe
Stock Ownership - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen